Photodynamic Therapy (PDT) is recognized for its exceptional effectiveness as a promising cancer treatment method. However, it is noted that overexposure to the dosage and sunlight in traditional PDT can result in damage to healthy tissues, due to the low tumor selectivity of currently available photosensitizers (PSs). To address this challenge, we introduce herein a new strategy where the small molecule-targeted agent, erlotinib, is integrated into a boron dipyrromethene (BODIPY)-based PS to form conjugate 6 to enhance the precision of PDT. This conjugate demonstrates optical absorption, fluorescence emission, and singlet oxygen generation efficiency comparable to the reference compound 7, which lacks erlotinib. In vitro studies reveal that, after internalization, conjugate 6 predominantly accumulates in the lysosomes of HepG2 cells, exhibiting significant photocytotoxicity with an IC50 value of 3.01 µM. A distinct preference for HepG2 cells over HELF cells is observed with conjugate 6 but not with compound 7. In vivo experiments further confirm that conjugate 6 has a specific affinity for tumor tissues, and the combination treatment of conjugate 6 with laser illumination can effectively eradicate H22 tumors in mice with outstanding biosafety. This study presents a novel and potential PS for achieving precise PDT against cancer.
The incorporation of alkene bonds into aromatic heterocyclic skeletons offers an efficient and straightforward strategy for molecular splicing and extension of conjugated systems, while also paving the way for the development of novel functional molecules. However, conventional approaches often depend on aldehyde or ketone precursors, involve multistep sequences, or require harsh reaction conditions, which considerably restrict their applicability. Herein, we present a single-step photoinduced alkene coupling reaction using quinoxalinones and indoleones that proceeds in high yield within a recyclable ionic liquid medium. This process exploits the inherent photosensitivity of the substrates to achieve autocatalysis, eliminating the need for an external photocatalyst, and proceeds under mild conditions with only a stoichiometrically minimal amount of oxidant. The method demonstrates strict stereoselectivity, broad substrate scope, and good functional group tolerance. Mechanistic investigations indicate a radical-based mechanism, wherein photoexcitation generates radical species that are regenerated via hydrogen atom transfer between the photoactive substrate and the radical intermediate. Given the significance of aromatic heterocyclic conjugated systems in pharmaceuticals and energy-related materials, this photocatalytic alkene coupling strategy holds considerable potential for practical applications.